Healthcare >> CEO Interviews >> September 30, 1999
CHRISTOPHER MIRABELLI, Ph.D., has served as Chairman of the Board of
Directors and Chief Executive Officer of LeukoSite, Inc. since July
1993. During Dr. Mirabelli's six year tenure, the company has become a
leader in the discovery and development of therapeutics based on the
biology of leukocytes (white blood cells) with potential applications in
cancer and inflammatory, autoimmune and viral diseases. Under his
leadership, LeukoSite has raised over $100MM in private, corporate and
public equity financing, established corporate R&D alliances with major
U.S.-, European- and Japanese-based pharmaceutical companies and has
constructed a pipeline of multiple product opportunities spanning late
phase clinical development and early research and drug discovery. Dr.
Mirabelli was a Founder of Isis Pharmaceuticals, Inc., where he served
as Executive Vice President from 1992 to 1993, Senior Vice President of
Research and Preclinical Development from 1991 to 1992, and Vice
President of Research from 1989 to 1991. He was a member of Smith Kline
and French Laboratories, R&D Division from 1981-1988, where he held a
number of positions including Director of the Department of Molecular
Pharmacology. Dr. Mirabelli received his Ph.D. degree in Molecular
Pharmacology from Baylor College of Medicine in Houston, Texas in 1981.
Dr. Mirabelli is currently a member of the Board of Directors of the
Massachusetts Biotechnology Council and the Emerging Companies Section
Governing Body of BIO. Profile
the company just to set the stage for the readers?
Dr. Mirabelli: LeukoSite is an emerging biopharmaceutical company with
